101 related articles for article (PubMed ID: 11098489)
21. UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
Minsky BD
Int J Cancer; 2001 Feb; 96(1):1-10. PubMed ID: 11241325
[TBL] [Abstract][Full Text] [Related]
22. Postsurgical sequential methotrexate/5-FU and leucovorin on outpatient basis for advanced colorectal carcinoma.
Tokunaga Y; Kitaoka A; Yagi T; Tokuka A; Ohsumi K
Hepatogastroenterology; 2001; 48(37):128-32. PubMed ID: 11268947
[TBL] [Abstract][Full Text] [Related]
23. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
24. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
25. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
26. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
[TBL] [Abstract][Full Text] [Related]
27. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
Kawasaki G; Yoshitomi I; Yanamoto S; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Dec; 94(6):717-23. PubMed ID: 12464897
[TBL] [Abstract][Full Text] [Related]
28. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
[TBL] [Abstract][Full Text] [Related]
29. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
[TBL] [Abstract][Full Text] [Related]
30. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
31. Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
Ishizuka M; Kubota K; Nemoto T; Shimoda M; Kato M; Iso Y; Tago K
Asian J Surg; 2016 Jul; 39(3):149-54. PubMed ID: 26123137
[TBL] [Abstract][Full Text] [Related]
32. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study.
Thongprasert S; Maoleekoonpairoj S; Laohavinij S; Thavichaigarn P
J Med Assoc Thai; 2000 Jun; 83(6):676-80. PubMed ID: 10932496
[TBL] [Abstract][Full Text] [Related]
35. [Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT].
Kawasaki G; Yoshitomi I; Yanamoto S; Yamada S; Kawano T; Mizuno A
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1035-9. PubMed ID: 20567103
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacokinetic study in biochemical modulation therapy of UFT with leucovorin tablet].
Yamamura T; Oikawa H; Hanai A; Matsuzaki H; Akaishi O; Seo K; Kikuchi K; Ozasa T; Tsukikawa S; Yamaguchi S
Gan To Kagaku Ryoho; 1995 Feb; 22(2):245-51. PubMed ID: 7857100
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
Hoff PM; Pazdur R
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):48-50. PubMed ID: 10442361
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between antitumor activity and the inhibition of thymidylate synthase after oral administration of UFT in nude mice bearing human tumor].
Fujita M; Fujita F; Uchida J; Takeda S; Yamada Y; Taguchi T
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):627-32. PubMed ID: 2108611
[TBL] [Abstract][Full Text] [Related]
39. UFT plus leucovorin for metastatic colorectal cancer: Japanese experience.
Ichikawa W; Nihei Z; Uetake H; Yamada H; Shirota Y; Sugihara K
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):41-3. PubMed ID: 11098491
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Kuwata K; Nagayama S; Hirakawa Y; Matsushima E; Kawaguchi Y
Gan To Kagaku Ryoho; 2000 Jun; 27(6):885-90. PubMed ID: 10897216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
